title: Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus.
abstract: Control of hyperglycaemia is a fundamental therapeutic goal in patients with type 2 diabetes. The progressive nature of β-cell dysfunction in type 2 diabetes leads to the need for escalating anti-hyperglycaemic treatment, including insulin, in most patients. Given the prevalence of complications such as weight gain and hypoglycaemia associated with traditional anti-hyperglycaemic agents (AHA), including sulphonylureas and insulin, it is unsurprising that recent years have seen the development of novel agents to treat hyperglycaemia. With increasing evidence supporting the need for a multi-faceted approach to the prevention of adverse cardiovascular events in people with type 2 diabetes, a patient-centred and individualised management strategy addressing lifestyle, cardiovascular risk factor modification and glycaemic control remains critical in improving outcomes in these patients.
authors.affiliation: Department of Endocrinology, The Royal Hobart Hospital, Hobart, Tasmania, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Galligan
authors.affiliation: Department of Endocrinology, The Royal Hobart Hospital, Hobart, Tasmania, Australia.|The School of Medicine, Faculty of Health Science, University of Tasmania, Hobart, Tasmania, Australia.
authors.forename: T M
authors.initials: TM
authors.lastname: Greenaway
mesh_terms: D050110:Bariatric Surgery; D001786:Blood Glucose; D002318:Cardiovascular Diseases / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D045162:Thiazolidinediones / Q000627:therapeutic use; D015430:Weight Gain
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D008687:Metformin
keywords: anti-hyperglycaemic agents; cardiovascular safety; novel and emerging therapies; type 2 diabetes